HCW Biologics Statistics
Share Statistics
HCW Biologics has 1.12M
shares outstanding. The number of shares has increased by -0.19%
in one year.
| Shares Outstanding | 1.12M |
| Shares Change (YoY) | -0.19% |
| Shares Change (QoQ) | -0.19% |
| Owned by Institutions (%) | 8.27% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 80 |
| FTD / Avg. Volume | 0.01% |
Short Selling Information
The latest short interest is 6.92K, so 0.62% of the outstanding
shares have been sold short.
| Short Interest | 6.92K |
| Short % of Shares Out | 0.62% |
| Short % of Float | 1.03% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
The PE ratio is -23.05 and the forward
PE ratio is -18.8.
HCW Biologics's PEG ratio is
-2.31.
| PE Ratio | -23.05 |
| Forward PE | -18.8 |
| PS Ratio | 269.62 |
| Forward PS | 0.2 |
| PB Ratio | -102.22 |
| P/FCF Ratio | -47.76 |
| PEG Ratio | -2.31 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for HCW Biologics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.19,
with a Debt / Equity ratio of -2.02.
| Current Ratio | 0.19 |
| Quick Ratio | 0.19 |
| Debt / Equity | -2.02 |
| Debt / EBITDA | -0.49 |
| Debt / FCF | -0.95 |
| Interest Coverage | -25.45 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $71,299.78 |
| Profits Per Employee | $-833,994.83 |
| Employee Count | 36 |
| Asset Turnover | 0.08 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -80.8% in the
last 52 weeks. The beta is 0.86, so HCW Biologics's
price volatility has been higher than the market average.
| Beta | 0.86 |
| 52-Week Price Change | -80.8% |
| 50-Day Moving Average | 9.99 |
| 200-Day Moving Average | 16.79 |
| Relative Strength Index (RSI) | 52.38 |
| Average Volume (20 Days) | 638,111 |
Income Statement
In the last 12 months, HCW Biologics had revenue of 2.57M
and earned -30.02M
in profits. Earnings per share was -0.77.
| Revenue | 2.57M |
| Gross Profit | 959.4K |
| Operating Income | -29.48M |
| Net Income | -30.02M |
| EBITDA | -27.68M |
| EBIT | -28.87M |
| Earnings Per Share (EPS) | -0.77 |
Full Income StatementBalance Sheet
The company has 4.67M in cash and 13.69M in
debt, giving a net cash position of -9.02M.
| Cash & Cash Equivalents | 4.67M |
| Total Debt | 13.69M |
| Net Cash | -9.02M |
| Retained Earnings | -100.56M |
| Total Assets | 30.24M |
| Working Capital | -23.93M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -14.23M
and capital expenditures -261.62K, giving a free cash flow of -14.49M.
| Operating Cash Flow | -14.23M |
| Capital Expenditures | -261.62K |
| Free Cash Flow | -14.49M |
| FCF Per Share | -0.37 |
Full Cash Flow StatementMargins
Gross margin is 37.38%, with operating and profit margins of -1148.5% and -1169.7%.
| Gross Margin | 37.38% |
| Operating Margin | -1148.5% |
| Pretax Margin | -1169.7% |
| Profit Margin | -1169.7% |
| EBITDA Margin | -1078.43% |
| EBIT Margin | -1148.5% |
| FCF Margin | -564.48% |
